Molnupiravir – July 2023

• Brand names:
  • Lagevrio®
• Pharmaceutical Company:
  • Merck Sharp & Dohme (Australia) Pty Ltd
• Condition/Indication: Mild to moderate COVID-19
• Meeting Date: July 2023
• Public Summary Document (PSD) July 2023 November 2023 PBAC Meetings - (PDF 1.8 MB)
• Public Summary Document (PSD) July 2023 November 2023 PBAC Meetings - (Word 934 KB)

Related Public Summary Documents

• Molnupiravir – November 2023